{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibvlcmanaogsckul25mmmn23jnsthei256t7pgawqboy4piry7ppa",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3meb2pm76uyy2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicijmrgxvsy5d4ruyyyi7xaksysdoq4lfpuonvo3irtygagnfa5i4"
    },
    "mimeType": "image/jpeg",
    "size": 69828
  },
  "path": "/pharmalot/2026/02/06/fda-take-action-against-hims-telehealth-wegovy-compounding/?utm_campaign=rss",
  "publishedAt": "2026-02-07T01:05:16.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharmalot",
    "FDA",
    "Obesity",
    "Pharmaceuticals",
    "Policy",
    "public health",
    "STAT+"
  ],
  "textContent": "FDA will take “decisive steps” to thwart companies from mass marketing unapproved, compounded versions of GLP-1 drugs",
  "title": "STAT+: HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy",
  "updatedAt": "2026-02-07T01:30:39.000Z"
}